(Q36408733)

14 August 2017

1 reference

title

Combating influenza with antiviral therapy in the pediatric population (English)

1 reference

14 August 2017

Kara A Townsend

1

1 reference

14 August 2017

Lea S Eiland

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

26

1 reference

14 August 2017

issue

1

1 reference

14 August 2017

page(s)

95-103

1 reference

Reduction of the influenza burden in children

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.95

ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.95

Nosocomial transmission of influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.95

A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.95

Pandemic influenza: is an antiviral response realistic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.95

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.95

Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.95

Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.95

Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.95

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.95

Early administration of oral oseltamivir increases the benefits of influenza treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.95

Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.95

Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.95

Oral oseltamivir treatment of influenza in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.95

10.1592/PHCO.2006.26.1.95

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference